Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) EBIT Margin (2016 - 2025)

Ocular Therapeutix has reported EBIT Margin over the past 13 years, most recently at 526.49% for Q4 2025.

  • Quarterly results put EBIT Margin at 526.49% for Q4 2025, down 23041.0% from a year ago — trailing twelve months through Dec 2025 was 519.75% (down 25017.0% YoY), and the annual figure for FY2025 was 519.75%, down 25018.0%.
  • EBIT Margin for Q4 2025 was 526.49% at Ocular Therapeutix, down from 472.35% in the prior quarter.
  • Over the last five years, EBIT Margin for OCUL hit a ceiling of 127.41% in Q3 2023 and a floor of 597.47% in Q1 2025.
  • Median EBIT Margin over the past 5 years was 176.35% (2022), compared with a mean of 255.5%.
  • Biggest five-year swings in EBIT Margin: soared 96719bps in 2021 and later tumbled -38346bps in 2025.
  • Ocular Therapeutix's EBIT Margin stood at 146.64% in 2021, then increased by 6bps to 137.56% in 2022, then increased by 2bps to 135.46% in 2023, then plummeted by -119bps to 296.08% in 2024, then tumbled by -78bps to 526.49% in 2025.
  • The last three reported values for EBIT Margin were 526.49% (Q4 2025), 472.35% (Q3 2025), and 502.57% (Q2 2025) per Business Quant data.